Joseph C. Papa

CIK: 0001242215

Transaction Breakdown

Open Market Buys (P)1 (5.9%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)15 (88.2%)

Compensation grants

Other (G, F, J, C, D, …)1 (5.9%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

CADL

Candel Therapeutics, Inc.

Director

MIST

Milestone Pharmaceuticals Inc.

Director

EBS

Emergent BioSolutions Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (17 total)

CADL
Candel Therapeutics, Inc.
Sep 30, 2026
Award(A)
Stock Option (Right to Buy)
Direct
1.3K shares at avg. $8.68-
CADL
Candel Therapeutics, Inc.
Jun 30, 2026
Award(A)
Stock Option (Right to Buy)
Direct
1.3K shares at avg. $8.64-
CADL
Candel Therapeutics, Inc.
Jun 23, 2026
Award(A)
Stock Option (Right to Buy)
Direct
32K shares-
MIST
Milestone Pharmaceuticals Inc.
Jun 10, 2026
Award(A)
Stock Option (right to buy)
Direct
77K shares-
EBS
Emergent BioSolutions Inc.
Apr 29, 2026
Award(A)
Direct
187.7K shares-
CADL
Candel Therapeutics, Inc.
Mar 31, 2026
Award(A)
Stock Option (Right to Buy)
Direct
2.8K shares at avg. $4.11-
EBS
Emergent BioSolutions Inc.
Mar 5, 2026
Tax Payment(F)
Direct
37.1K shares at avg. $8.44$313K
EBS
Emergent BioSolutions Inc.
Mar 3, 2026
Award(A)
Employee Stock Option (Right to buy)
Direct
252.2K shares-
MIST
Milestone Pharmaceuticals Inc.
Jul 11, 2025
Award(A)
Direct
100K shares-
CADL
Candel Therapeutics, Inc.
Jun 25, 2025
Award(A)
Indirect
64.2K shares at avg. $4.67$300K
CADL
Candel Therapeutics, Inc.
Jun 17, 2025
Award(A)
Stock Option (Right to Buy)
Direct
14.2K shares-
MIST
Milestone Pharmaceuticals Inc.
Jun 10, 2025
Award(A)
Stock Option (right to buy)
Direct
40K shares-
EBS
Emergent BioSolutions Inc.
May 13, 2025
Purchase(P)
Direct
60K shares at avg. $5.83$350K
EBS
Emergent BioSolutions Inc.
Mar 12, 2025
Award(A)
Employee Stock Options (Right to Buy)
Direct
250K shares-
EBS
Emergent BioSolutions Inc.
Mar 12, 2025
Award(A)
Employee Stock Options (Right to Buy)
Direct
250K shares-
EBS
Emergent BioSolutions Inc.
Mar 6, 2025
Award(A)
Direct
282.5K shares-
MIST
Milestone Pharmaceuticals Inc.
Sep 3, 2024
Award(A)
Stock Option (right to buy)
Direct
80K shares-

		Type	Shares	Price		Ownership
Sep 30, 2026	CADL Candel Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	1,325	$8.68	-	Direct
Jun 30, 2026	CADL Candel Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	1,331	$8.64	-	Direct
Jun 23, 2026	CADL Candel Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	32,000	-	-	Direct
Jun 10, 2026	MIST Milestone Pharmaceuticals Inc.	Award(A) Stock Option (right to buy)	77,000	-	-	Direct
Apr 29, 2026	EBS Emergent BioSolutions Inc.	Award(A)	187,708	-	$0	Direct
Mar 31, 2026	CADL Candel Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	2,795	$4.11	-	Direct
Mar 5, 2026	EBS Emergent BioSolutions Inc.	Tax Payment(F)	37,055	$8.44	$312,744	Direct
Mar 3, 2026	EBS Emergent BioSolutions Inc.	Award(A) Employee Stock Option (Right to buy)	252,194	-	-	Direct
Jul 11, 2025	MIST Milestone Pharmaceuticals Inc.	Award(A)	100,000	-	-	Direct
Jun 25, 2025	CADL Candel Therapeutics, Inc.	Award(A)	64,239	$4.67	$299,996	Indirect
Jun 17, 2025	CADL Candel Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	14,240	-	-	Direct
Jun 10, 2025	MIST Milestone Pharmaceuticals Inc.	Award(A) Stock Option (right to buy)	40,000	-	-	Direct
May 13, 2025	EBS Emergent BioSolutions Inc.	Purchase(P)	60,000	$5.83	$349,800	Direct
Mar 12, 2025	EBS Emergent BioSolutions Inc.	Award(A) Employee Stock Options (Right to Buy)	250,000	-	-	Direct
Mar 12, 2025	EBS Emergent BioSolutions Inc.	Award(A) Employee Stock Options (Right to Buy)	250,000	-	-	Direct
Mar 6, 2025	EBS Emergent BioSolutions Inc.	Award(A)	282,500	-	-	Direct
Sep 3, 2024	MIST Milestone Pharmaceuticals Inc.	Award(A) Stock Option (right to buy)	80,000	-	-	Direct

1-17 of 17 transactions

About PAPA JOSEPH C

PAPA JOSEPH C (SEC CIK 0001242215) files insider reports with the SEC as Director of Candel Therapeutics, Inc. (CADL), Director of Milestone Pharmaceuticals Inc. (MIST) and President and CEO of Emergent BioSolutions Inc. (EBS).

Signal8 holds 16 ownership filings by PAPA JOSEPH C (1 Form 3, 15 Form 4), filed between Sep 5, 2024 and Oct 2, 2026. Those filings report 17 transactions, from Sep 3, 2024 to Sep 30, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on PAPA JOSEPH C's filings is in NEEDHAM, MA.

Recent filings by PAPA JOSEPH C

Sep 30, 2026: Grant or award of CADL derivative securities (Form 4, code A).
Jun 30, 2026: Grant or award of CADL derivative securities (Form 4, code A).
Jun 23, 2026: Grant or award of CADL derivative securities (Form 4, code A).
Jun 10, 2026: Grant or award of MIST derivative securities (Form 4, code A).
Apr 29, 2026: Grant or award of EBS shares (Form 4, code A).

Other insiders filing for Candel Therapeutics, Inc. (CADL)

Loggia Nicoletta, Director
Manning Paul B, Director
Tak Paul Peter, Chief Executive Officer
Zimmermann Martine, Director
Tyagarajan Seshu, Chief Technology Officer
Sims Mark E., Chief Commercial Officer

How to read Form 4 transaction codes